New Hope honored by FDA
This article was originally published in The Tan Sheet
The agency bestows its Civilian Honor Award in the Leveraging/Collaboration category on New Hope Natural Media's standards program. The program, which launched in 1994, is part of an industry-wide effort to encourage self-regulation and cooperation, Boulder, Colo.-based New Hope said June 4. Fred Linder, the media firm's senior VP, said the honor is a significant achievement given that the agency "is not known for giving out gratuitous awards." Linder and his colleagues will receive the distinction at the June 26 Office of Regulatory Affairs Honor Awards ceremony in Washington
You may also be interested in...
The firm licensed the TLR9 agonist SD-101 from Dynavax to test with its pressure-enabled drug delivery technology in liver and pancreatic settings where immuno-oncology has shown moderate efficacy or less.
Given inconsistent study results, robustness of the efficacy evidence is expected to be key focus of the 6 November meeting of the Peripheral and Central Nervous System Drugs Advisory Committee; review could put a December 2019 guidance on the ‘substantial evidence’ standard to the test and offer insight into the amount of flexibility the agency is willing to exercise for neurodegenerative diseases with high unmet need.
CRLs FDA submits in response to ANDAs increased most years since FY 2015, though FY 2020 total likely will be lower than two previous years. A 2019 CRL interrupted GSK's plans to market first mouth spray nicotine replacement therapy in US.